Welcome to our dedicated page for Werewolf Therapeutics news (Ticker: HOWL), a resource for investors and traders seeking the latest updates and insights on Werewolf Therapeutics stock.
News about Werewolf Therapeutics, Inc. (Nasdaq: HOWL) centers on its progress in developing conditionally activated immune therapies for cancer and other immune-mediated conditions. Company announcements frequently highlight updates from its PREDATOR platform, which is used to design INDUKINE cytokine prodrugs and INDUCER T cell engager candidates that aim to stimulate adaptive and innate immunity while limiting systemic toxicity.
Investors and followers of HOWL can expect regular news on the clinical development of WTX-124 and WTX-330, Werewolf’s most advanced INDUKINE programs. Press releases describe Phase 1/1b and Phase 1b/2 trial updates in multiple advanced solid tumors, regulatory designations such as Fast Track status for WTX-124 in cutaneous melanoma after standard immunotherapy, and emerging data on tolerability, antitumor activity, and tumor-selective activation strategies.
News flow also covers the company’s expanding INDUCER T cell engager platform, including preclinical data for WTX-1011, an anti‑STEAP1 candidate for STEAP1-expressing cancers, and WTX-2022, targeting CDH6-expressing cancers. Werewolf reports on presentations at scientific and medical meetings, such as the Society for Immunotherapy of Cancer’s Annual Meeting and disease-focused summits, where it shares data on sequential dosing of IL‑12 and IL‑2 INDUKINE molecules, masking strategies to reduce cytokine release, and real-time pharmacokinetic insights.
Additional HOWL news items include quarterly financial results, business updates, conference participation, and partnering discussions around its broader INDUKINE portfolio, including WTX-712, WTX-518, and WTX-921. For readers tracking immuno-oncology developments, the Werewolf Therapeutics news page provides a consolidated view of clinical milestones, regulatory interactions, scientific presentations, and corporate strategy disclosures related to the company’s conditionally activated immune therapeutics.
Werewolf Therapeutics, a biopharmaceutical company listed on Nasdaq as HOWL, announced that its CEO, Daniel J. Hicklin, Ph.D., will present at the Jefferies Virtual Healthcare Conference on June 3rd at 11 am ET. The company focuses on engineering conditionally activated therapeutics to enhance the immune system for cancer treatment. Their proprietary PREDATOR™ platform aims to create molecules that activate specifically in the tumor microenvironment. WTX-124 and WTX-330 are two leading candidates currently in preclinical studies.
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) announced the pricing of its upsized initial public offering (IPO) of 7,500,000 shares at $16.00 each, yielding approximately $120 million in gross proceeds. An option for underwriters to purchase an additional 1,125,000 shares is also granted. Trading on the Nasdaq Global Select Market begins on April 30, 2021, with the offering closing anticipated on May 4, 2021. The company focuses on developing immunotherapeutics for cancer treatment, leveraging its PREDATOR™ platform.